Neovant Therapeutics Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 07-01-2025
- Paid Up Capital ₹ 0.15 M
as on 07-01-2025
- Company Age 1 Year 11 Months
- Open Charges ₹ 1.95 Cr
as on 07-01-2025
About Neovant Therapeutics
The Company is engaged in the Pharma Industry.
The Company's status is Active It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.15 M.
The company currently has active open charges totaling ₹1.95 Cr.
Dashrathbhai Patel, Dilip Chaudhary, Jagdish Chaudhary, and Five other members serve as directors at the Company.
- CIN/LLPIN
U21002GJ2023PTC138826
- Company No.
138826
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Feb 2023
- Date of AGM
-
- Date of Balance Sheet
-
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Mahesana, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Neovant Therapeutics?
Board Members (8)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nirav Trivedi  | Director | 10-Mar-2023 | Current |
| Dashrathbhai Patel | Director | 10-Mar-2023 | Current |
| Dilip Chaudhary | Director | 23-Feb-2023 | Current |
| Jagdish Chaudhary | Director | 23-Feb-2023 | Current |
| Patwa Ajaybhai | Director | 10-Mar-2023 | Current |
| Ramakrishna Guduru | Director | 10-Mar-2023 | Current |
Financial Performance of Neovant Therapeutics.
Enhance accessibility to Neovant Therapeutics's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Neovant Therapeutics?
Unlock access to Neovant Therapeutics's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Zasya Life Sciences Private LimitedActive 3 years 2 monthsDilip Chaudhary, Nirav Trivedi and 1 more are mutual person
Shankus Pharma Private LimitedActive 3 years 2 monthsDilip Chaudhary and Jagdish Chaudhary are mutual person
Keshav Holiday Resort Pvt LtdActive 32 years 8 monthsDilip Chaudhary and Jagdish Chaudhary are mutual person
Charges (Loans)
₹19.50 M
₹0
Charges Breakdown by Lending Institutions
- State Bank Of India : 1.95 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 26 Dec 2023 | State Bank Of India | ₹1.95 Cr | Open |
How Many Employees Work at Neovant Therapeutics?
Unlock and access historical data on people associated with Neovant Therapeutics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Neovant Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Neovant Therapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.